Joel E. Gallant
Impact in
- Virology top 0.05%
- HIV Research and Treatment
- Infectious Diseases top 0.02%
- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- Antifungal resistance and susceptibility
Papers in
-
- HIV/AIDS drug development and treatment 108
- HIV/AIDS Research and Interventions 51
- Antifungal resistance and susceptibility 4
- Virology 25
- HIV Research and Treatment 25
- Co-authors
- Richard E. Chaisson (16 shared papers)Robert F. Siliciano (12 shared papers)Richard D. Moore (17 shared papers)Thomas C. Quinn (6 shared papers)Diana Finzi (2 shared papers)Theodore C. Pierson (2 shared papers)Karen R. Chadwick (2 shared papers)Jeanne C. Keruly (10 shared papers)
- Journals
- Clinical Infectious Diseases (26 papers)AIDS (21 papers)JAIDS Journal of Acquired Immune Deficiency Syndromes (16 papers)The Journal of Infectious Diseases (13 papers)Open Forum Infectious Diseases (8 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Joel E. Gallant
197 papers receiving 25.1k citations
Joel E. Gallant's Hit Papers
Peers
Comparison fields: 5 of 162
- Virology 5.9k
- Infectious Diseases 15.8k
- Emergency Medicine 2k
- Epidemiology 1.9k
- Family Practice 131
Countries citing papers authored by Joel E. Gallant
This map shows the geographic impact of Joel E. Gallant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel E. Gallant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel E. Gallant more than expected).
Fields of papers citing papers by Joel E. Gallant
This network shows the impact of papers produced by Joel E. Gallant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel E. Gallant. The network helps show where Joel E. Gallant may publish in the future.
Co-authors
The 25 scholars most cited alongside Joel E. Gallant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Prevention of HIV-1 Infection with Early Antiretroviral Therapy Hit paper breakdown → | 2011 | 5709 |
| 2 | Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy Hit paper breakdown → | 1997 | 2637 |
| 3 | Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Hit paper breakdown → | 1999 | 1793 |
| 4 | Antiretroviral Therapy for the Prevention of HIV-1 Transmission Hit paper breakdown → | 2016 | 1324 |
| 5 | Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients A 3-Year Randomized Trial Hit paper breakdown → | 2004 | 1191 |
| 6 | Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV Hit paper breakdown → | 2006 | 763 |
| 7 | Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults Hit paper breakdown → | 2016 | 563 |
| 8 | Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine Hit paper breakdown → | 1992 | 470 |
| 9 | Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial Hit paper breakdown → | 2014 | 411 |
| 10 | Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America Hit paper breakdown → | 2013 | 406 |
| 11 | Antiretroviral Treatment of Adult HIV Infection Hit paper breakdown → | 2014 | 403 |
| 12 | Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks Hit paper breakdown → | 2012 | 398 |
| 13 | Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America Hit paper breakdown → | 2009 | 397 |
| 14 | 2003 | 395 | |
| 15 | 2006 | 365 | |
| 16 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Hit paper breakdown → | 2017 | 314 |
| 17 | 2014 | 299 | |
| 18 | 2005 | 255 | |
| 19 | Medical Management of HIV Infection | 1996 | 226 |
| 20 | 2013 | 224 |
About Joel E. Gallant
Joel E. Gallant is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Epidemiology and Hepatology, having authored 202 papers that have together received 26.3k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (108 papers), HIV/AIDS Research and Interventions (51 papers), HIV Research and Treatment (25 papers), HIV-related health complications and treatments (18 papers), Pneumocystis jirovecii pneumonia detection and treatment (9 papers), Viral-associated cancers and disorders (5 papers), Antifungal resistance and susceptibility (4 papers) and Hepatitis C virus research (4 papers). The work is most often cited by research in Virology (5.9k citations), Infectious Diseases (15.8k citations), Emergency Medicine (2k citations), Epidemiology (1.9k citations) and Family Practice (131 citations). Joel E. Gallant has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Richard E. Chaisson, Robert F. Siliciano, Richard D. Moore, Thomas C. Quinn, Diana Finzi, Theodore C. Pierson, Karen R. Chadwick, Jeanne C. Keruly, Andrew Cheng and Joseph B. Margolick. Their work appears in journals such as Clinical Infectious Diseases, AIDS, JAIDS Journal of Acquired Immune Deficiency Syndromes, The Journal of Infectious Diseases and Open Forum Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.